Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline: 4Q16

Although approvals were down year-on-year, December saw a rash of drug registrations, which included innovative products like MACI (autologous chondrocytes on an implantable artificial matrix), the antisense molecule Spinraza (nusinersen), and Zinplava, a fully human monoclonal antibody that targets Clostridium difficile toxin B. However, complete response letters predominated more than in previous quarters, with setbacks for Cempra's solithera and Regeneron's sarilumab. Decisions on several biosimilars are on the horizon.

Historic US regulatory approvals by lead indication

Notable clinical trial results (4Q16)

Notable regulatory approvals (4Q16)

Notable regulatory setbacks (4Q16)

Notable upcoming regulatory decisions (1Q17)

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Drug pipeline: 4Q16. Nat Biotechnol 35, 107 (2017). https://doi.org/10.1038/nbt.3797

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing